Developer docs
API playgroundTry for free, no card

Search company profiles

BioIMeD

Full company profile

uuid0022yx6

Namestring
BioIMeD
Legal namestring
Bio IMeD S.r.l.
Websiteurl
bioimed.it
Company typeenum
Private
Founded yearint
2022
Descriptiontext

BioIMeD (legally Bio IMeD S.r.l.) is an Italian medical device startup founded around 2019 and headquartered in Trieste that develops AI-based products for disease diagnosis, treatment, and monitoring. The company sells two flagship products to healthcare providers, hospitals, anatomopathologists, and local health authorities: BiopIA, an automated liquid biopsy device that integrates microfiltration, a microfluidic chip, precision sensors, optical imaging, and machine learning software to acquire and analyze blood samples with claimed 90% diagnostic accuracy, 100% cellular recovery, and a 10x reduction in analysis time; and DomotIA, a remote patient monitoring platform offered as Infrastructure as a Service, which uses IoT sensors, cloud computing, and AI-based anomaly detection for continuous monitoring of elderly and chronic disease patients.

The technology stack combines proprietary hardware (microfluidic consumables, optical acquisition systems) with in-house computer vision and anomaly detection AI algorithms, the latter optimized by a dedicated computer engineering sub-team. BioIMeD's commercial model is direct sales of BiopIA devices to hospitals and clinical laboratories, paired with a managed-services IaaS offering for DomotIA; both go to market through direct channels, exclusively in Italy. Validation has been pursued through a clinical trial at Trieste's Cattinara Hospital and an announced research collaboration with Fondazione Italiana Fegato for liver disease applications, and the company holds a European patent application for the integrated BiopIA architecture.

The company's capital base is thin — approximately €39,550 raised via a 2019 POR FESR 2014-2020 grant — with a six-member multidisciplinary team spanning biomedical device engineering, clinical/regulatory affairs, and academic scientific leadership (Prof. Agostino Accardo as CSO). BioIMeD has received multiple Italian innovation awards (2019 StartCup FVG, Premio Nazionale Innovazione, AIIC special Healthcare Innovation recognition, Contamination Cup) and completed a CSA STAR Level 1 cloud security self-assessment in October 2022. No commercial revenue or subsequent funding rounds have been disclosed.

Short descriptiontext

BioIMeD is an Italian medical device startup based in Trieste that builds AI-based products for disease diagnosis and monitoring — BiopIA, an automated liquid biopsy device using computer vision, and DomotIA, a remote patient monitoring platform offered as a service to hospitals and clinicians.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTrieste, Italy
HQ citystring
Trieste
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy devices, AI medical diagnostics, remote patient monitoring, microfluidic diagnostics, IoT healthcare monitoring
Industry4 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Diagnostic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (BiopIA)
TypeHardware Sales
Description

Sale of automated liquid biopsy diagnostic devices to hospitals, laboratories, and healthcare facilities. Two versions are being developed: a laboratory version for use with optical microscopes and a standalone version with integrated optics.

bioimed.it
2DomotIA Platform (IaaS)
TypeManaged Services
Description

Remote patient monitoring platform offered as Infrastructure as a Service (IaaS) to healthcare providers and systems, enabling continuous monitoring of chronic disease patients

bioimed.it
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DomotIA
Description

Remote domotic system for patient monitoring based on IoT solutions for healthcare operators and patients. Sensors collect patient data, cloud computing stores and analyzes data, web and mobile applications make data accessible to doctors and patients.

bioimed.it
+1 more record
Core offering1 text field

BioIMeD develops AI-based intelligent medical devices that combine microfiltration, microfluidics, precision optical sensors, and machine learning software for diagnostic and monitoring applications. The company sells two main product lines: BiopIA, an automated liquid biopsy device for cancer diagnosis that delivers 100% cellular recovery and 90% diagnostic accuracy with over 10x reduction in analysis time, and DomotIA, an IoT-based remote patient monitoring platform offered as IaaS (Infrastructure as a Service) to healthcare systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 90% diagnostic accuracy demonstrated during clinical trials
+5 more records
Product overview1 text field

BioIMeD develops two main AI-based medical device products: BiopIA, an automated liquid biopsy device that combines microfiltration, microfluidic chips, precision sensors, optical imaging, and AI software to isolate and identify cancer cells from blood samples, achieving approximately 90% diagnostic accuracy and 100% cellular recovery while reducing analysis time by over 10x; and DomotIA, a remote IoT-based patient monitoring platform for healthcare operators and patients that collects continuous sensor data, processes it through cloud algorithms to detect anomalous behaviors, and delivers real-time alerts via web and mobile applications.

Product and service1 record
1BiopIA
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Ospedale Cattinara di Trieste
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Clinical trial partnership for testing the BiopIA liquid biopsy device. The hospital conducted initial tests and trials with promising results, achieving approximately 90% diagnostic accuracy. This partnership provided critical validation data for the device's performance.

bioimed.it
2Fondazione Italiana Fegato
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Upcoming research collaboration for device testing. BioIMeD will soon start new projects together with Fondazione Italiana Fegato to expand clinical validation of the BiopIA device in liver disease diagnostics.

bioimed.it
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Entrepreneurship program that nurtured the company's founding. The startup idea emerged during Simone Pennini's participation in the CLab program, where initial concept development and business mentorship occurred.

4Diego Sardon (Business Mentor)
Strategic tierMinorTypeOthers
Description

Business mentor and advisor, former CEO of Prodigys Technology and Bilimetrix. Joined the team to provide business expertise and network connections that helped advance the startup's development and partnerships.

bioimed.it
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

bioMérieux operates FilmArray and other molecular diagnostic instrument lines for clinical and industrial microbiology, with growing oncology exposure. Directly comparable to BiopIA as a manufacturer of automated clinical diagnostic instruments combining sample prep, optics, and algorithmic interpretation.

TypeDirect peer
Description

Cepheid's GeneXpert system is the leading fully automated molecular diagnostic platform used in hospitals globally, including oncology and infectious disease assays. Directly comparable to BiopIA in pursuing cartridge-based, fully automated diagnostic workflow for clinical labs.

TypeRegional player
Description

Menarini Diagnostics is an Italy-headquartered diagnostic and medical device manufacturer distributing point-of-care and laboratory instrumentation across Europe. Comparable as a same-country diagnostics platform targeting Italian hospital laboratories, though it operates across a much broader product portfolio than BioIMeD.

4GRAIL
TypeBroad incumbent
Description

GRAIL is a well-capitalized liquid biopsy company developing multi-cancer early detection tests (Galleri). Tangentially comparable to BiopIA because both target blood-based cancer detection, but GRAIL operates at the assay/clinic level rather than as an instrument manufacturer and represents the competitive end-product on BioIMeD's installed base.

TypeDirect peer
Description

Bio-Techne's Diagnostics & Genomics segment includes liquid-biopsy reagents (ExoDx), instruments, and analytical platforms used by clinical labs. Directly comparable to BiopIA in the liquid biopsy reagent/instrument market targeting clinical pathology customers.

TypeDirect peer
Description

QIAGEN provides sample-preparation kits and circulating-tumor-cell / cell-free-DNA liquid biopsy technologies plus automation platforms (QIAcube, QIAsymphony). Directly comparable to BiopIA in supplying liquid biopsy workflows and lab automation consumables to molecular pathology labs.

7Biofourmis
TypeDirect peer
Description

Biofourmis is an AI-driven remote patient monitoring and virtual care platform for chronic disease management. Directly comparable to DomotIA in combining IoT, cloud, and AI algorithms to detect clinical deterioration and trigger interventions for chronic and post-acute patients.

TypeEmerging player
Description

Guardant Health is a liquid biopsy specialist focused on circulating tumor DNA for oncology diagnostics. Partial overlap with BiopIA: both operate in cancer liquid biopsy, but BioIMeD builds the automation hardware platform rather than the assay itself.

TypeDirect peer
Description

Tunstall provides telecare, telehealth, and remote patient monitoring solutions including ambient assisted living, primarily to European health and social care providers. Directly comparable to DomotIA in selling technology-enabled continuous monitoring services into European public health authorities.

TypeDirect peer
Description

Biocartis develops the Idylla molecular diagnostic platform, an automated cartridge-based system for oncology and liquid biopsy testing. Directly comparable to BiopIA in that both target integrated, sample-to-result automation in molecular oncology diagnostics for hospital laboratories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioIMeD

Diagnostic Medical Devicesbioimed.it

BioIMeD is an Italian medical device startup based in Trieste that builds AI-based products for disease diagnosis and monitoring — BiopIA, an automated liquid biopsy device using computer vision, and DomotIA, a remote patient monitoring platform offered as a service to hospitals and clinicians.

What BioIMeD does

BioIMeD (legally Bio IMeD S.r.l.) is an Italian medical device startup founded around 2019 and headquartered in Trieste that develops AI-based products for disease diagnosis, treatment, and monitoring. The company sells two flagship products to healthcare providers, hospitals, anatomopathologists, and local health authorities: BiopIA, an automated liquid biopsy device that integrates microfiltration, a microfluidic chip, precision sensors, optical imaging, and machine learning software to acquire and analyze blood samples with claimed 90% diagnostic accuracy, 100% cellular recovery, and a 10x reduction in analysis time; and DomotIA, a remote patient monitoring platform offered as Infrastructure as a Service, which uses IoT sensors, cloud computing, and AI-based anomaly detection for continuous monitoring of elderly and chronic disease patients.

The technology stack combines proprietary hardware (microfluidic consumables, optical acquisition systems) with in-house computer vision and anomaly detection AI algorithms, the latter optimized by a dedicated computer engineering sub-team. BioIMeD's commercial model is direct sales of BiopIA devices to hospitals and clinical laboratories, paired with a managed-services IaaS offering for DomotIA; both go to market through direct channels, exclusively in Italy. Validation has been pursued through a clinical trial at Trieste's Cattinara Hospital and an announced research collaboration with Fondazione Italiana Fegato for liver disease applications, and the company holds a European patent application for the integrated BiopIA architecture.

The company's capital base is thin — approximately €39,550 raised via a 2019 POR FESR 2014-2020 grant — with a six-member multidisciplinary team spanning biomedical device engineering, clinical/regulatory affairs, and academic scientific leadership (Prof. Agostino Accardo as CSO). BioIMeD has received multiple Italian innovation awards (2019 StartCup FVG, Premio Nazionale Innovazione, AIIC special Healthcare Innovation recognition, Contamination Cup) and completed a CSA STAR Level 1 cloud security self-assessment in October 2022. No commercial revenue or subsequent funding rounds have been disclosed.

BioIMeD firmographics

Firmographics
Name
BioIMeD
Legal name
Bio IMeD S.r.l.
Website
https://bioimed.it
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
BioIMeD is an Italian medical device startup based in Trieste that builds AI-based products for disease diagnosis and monitoring — BiopIA, an automated liquid biopsy device using computer vision, and DomotIA, a remote patient monitoring platform offered as a service to hospitals and clinicians.
Ownership category
akta.pro rank

BioIMeD industry classification

Industry
Product category
Diagnostic Medical Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Liquid biopsy devices
  • AI medical diagnostics
  • Remote patient monitoring
  • Microfluidic diagnostics
  • IoT healthcare monitoring

Where BioIMeD is headquartered

Location

Headquarters

HQ city
Trieste
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

BioIMeD business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (BiopIA): Sale of automated liquid biopsy diagnostic devices to hospitals, laboratories, and healthcare facilities. Two versions are being developed: a laboratory version for use with optical microscopes and a standalone version with integrated optics.
  2. DomotIA Platform (IaaS): Remote patient monitoring platform offered as Infrastructure as a Service (IaaS) to healthcare providers and systems, enabling continuous monitoring of chronic disease patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioIMeD product offering

Product offering

Core offering

BioIMeD develops AI-based intelligent medical devices that combine microfiltration, microfluidics, precision optical sensors, and machine learning software for diagnostic and monitoring applications. The company sells two main product lines: BiopIA, an automated liquid biopsy device for cancer diagnosis that delivers 100% cellular recovery and 90% diagnostic accuracy with over 10x reduction in analysis time, and DomotIA, an IoT-based remote patient monitoring platform offered as IaaS (Infrastructure as a Service) to healthcare systems.

Product overview

BioIMeD develops two main AI-based medical device products: BiopIA, an automated liquid biopsy device that combines microfiltration, microfluidic chips, precision sensors, optical imaging, and AI software to isolate and identify cancer cells from blood samples, achieving approximately 90% diagnostic accuracy and 100% cellular recovery while reducing analysis time by over 10x; and DomotIA, a remote IoT-based patient monitoring platform for healthcare operators and patients that collects continuous sensor data, processes it through cloud algorithms to detect anomalous behaviors, and delivers real-time alerts via web and mobile applications.

Differentiator

Problem solved

Functional benefit

Brands

  • DomotIA: Remote domotic system for patient monitoring based on IoT solutions for healthcare operators and patients. Sensors collect patient data, cloud computing stores and analyzes data, web and mobile applications make data accessible to doctors and patients.
  • BiopIA

Products and services

  • BiopIA

Quantifiable outcome

  • 90% diagnostic accuracy demonstrated during clinical trials
  • +5 more outcomes

Companies that use BioIMeD

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

BioIMeD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

BioIMeD partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Ospedale Cattinara di TriestecoreStrategic or Co-development Partner · 1 January 2019Clinical trial partnership for testing the BiopIA liquid biopsy device. The hospital conducted initial tests and trials with promising results, achieving approximately 90% diagnostic accuracy. This partnership provided critical validation data for the device's performance.
  • Fondazione Italiana FegatocoreStrategic or Co-development PartnerUpcoming research collaboration for device testing. BioIMeD will soon start new projects together with Fondazione Italiana Fegato to expand clinical validation of the BiopIA device in liver disease diagnostics.
  • CLab - Università degli Studi di TriesteminorStrategic or Co-development PartnerEntrepreneurship program that nurtured the company's founding. The startup idea emerged during Simone Pennini's participation in the CLab program, where initial concept development and business mentorship occurred.
  • Diego Sardon (Business Mentor)minorOthersBusiness mentor and advisor, former CEO of Prodigys Technology and Bilimetrix. Joined the team to provide business expertise and network connections that helped advance the startup's development and partnerships.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

BioIMeD competitors and assessment

Company assessment

Direct peers

  • bioMérieux: bioMérieux operates FilmArray and other molecular diagnostic instrument lines for clinical and industrial microbiology, with growing oncology exposure. Directly comparable to BiopIA as a manufacturer of automated clinical diagnostic instruments combining sample prep, optics, and algorithmic interpretation.
  • Cepheid (Danaher): Cepheid's GeneXpert system is the leading fully automated molecular diagnostic platform used in hospitals globally, including oncology and infectious disease assays. Directly comparable to BiopIA in pursuing cartridge-based, fully automated diagnostic workflow for clinical labs.
  • Bio-Techne: Bio-Techne's Diagnostics & Genomics segment includes liquid-biopsy reagents (ExoDx), instruments, and analytical platforms used by clinical labs. Directly comparable to BiopIA in the liquid biopsy reagent/instrument market targeting clinical pathology customers.
  • QIAGEN: QIAGEN provides sample-preparation kits and circulating-tumor-cell / cell-free-DNA liquid biopsy technologies plus automation platforms (QIAcube, QIAsymphony). Directly comparable to BiopIA in supplying liquid biopsy workflows and lab automation consumables to molecular pathology labs.
  • Biofourmis: Biofourmis is an AI-driven remote patient monitoring and virtual care platform for chronic disease management. Directly comparable to DomotIA in combining IoT, cloud, and AI algorithms to detect clinical deterioration and trigger interventions for chronic and post-acute patients.
  • Tunstall Healthcare: Tunstall provides telecare, telehealth, and remote patient monitoring solutions including ambient assisted living, primarily to European health and social care providers. Directly comparable to DomotIA in selling technology-enabled continuous monitoring services into European public health authorities.
  • Biocartis: Biocartis develops the Idylla molecular diagnostic platform, an automated cartridge-based system for oncology and liquid biopsy testing. Directly comparable to BiopIA in that both target integrated, sample-to-result automation in molecular oncology diagnostics for hospital laboratories.

Regional players

  • Menarini Diagnostics: Menarini Diagnostics is an Italy-headquartered diagnostic and medical device manufacturer distributing point-of-care and laboratory instrumentation across Europe. Comparable as a same-country diagnostics platform targeting Italian hospital laboratories, though it operates across a much broader product portfolio than BioIMeD.

Broad incumbents

  • GRAIL: GRAIL is a well-capitalized liquid biopsy company developing multi-cancer early detection tests (Galleri). Tangentially comparable to BiopIA because both target blood-based cancer detection, but GRAIL operates at the assay/clinic level rather than as an instrument manufacturer and represents the competitive end-product on BioIMeD's installed base.

Emerging players

  • Guardant Health: Guardant Health is a liquid biopsy specialist focused on circulating tumor DNA for oncology diagnostics. Partial overlap with BiopIA: both operate in cancer liquid biopsy, but BioIMeD builds the automation hardware platform rather than the assay itself.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BioIMeD social profiles

Digital presence

BioIMeD compliance and trust

Trust signal

Compliance1 record

BioIMeD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioIMeD leadership team

Management profile

Number of profiles

Profiles6 records

BioIMeD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioIMeD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioIMeD

What does BioIMeD do?

BioIMeD develops AI-based intelligent medical devices that combine microfiltration, microfluidics, precision optical sensors, and machine learning software for diagnostic and monitoring applications. The company sells two main product lines: BiopIA, an automated liquid biopsy device for cancer diagnosis that delivers 100% cellular recovery and 90% diagnostic accuracy with over 10x reduction in analysis time, and DomotIA, an IoT-based remote patient monitoring platform offered as IaaS (Infrastructure as a Service) to healthcare systems.

Is BioIMeD a public or private company?

BioIMeD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioIMeD founded?

BioIMeD was founded in 2022. It employs 1 to 10 people.

Where is BioIMeD based?

BioIMeD is headquartered in Trieste, Italy, in the Europe region.

How does BioIMeD make money?

Two revenue lines are on record. Medical Device Sales (BiopIA) is the primary driver. The others are domotIA Platform (IaaS).

Who are BioIMeD's main competitors?

Direct peers on record are bioMérieux, Cepheid (Danaher), Bio-Techne, QIAGEN, Biofourmis, Tunstall Healthcare and Biocartis. Menarini Diagnostics is listed as a regional player. GRAIL is listed as a broad incumbent. Guardant Health is listed as an emerging player.

Does BioIMeD have an API?

No public API is recorded for BioIMeD.

What industry is BioIMeD in?

BioIMeD's product category is Diagnostic Medical Devices. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales